Billiontoone (NASDAQ:BLLN) Insider Sells 4,000 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 4,000 shares of the business’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $140.21, for a total transaction of $560,840.00. Following the transaction, the insider directly owned 200,000 shares in the company, valued at approximately $28,042,000. The trade was a 1.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Thursday, July 9th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $125.00, for a total transaction of $1,000,000.00.
• On Wednesday, June 24th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $110.00, for a total value of $880,000.00.
• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total transaction of $785,760.00.

Billiontoone Trading Up 3.8%

Shares of BLLN stock traded up $5.20 during trading hours on Tuesday, hitting $142.52. The company had a trading volume of 657,241 shares, compared to its average volume of 503,173. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. The stock has a market capitalization of $6.55 billion and a PE ratio of 259.13. The company’s fifty day moving average is $114.39 and its 200 day moving average is $93.53. Billiontoone, Inc. has a fifty-two week low of $61.96 and a fifty-two week high of $144.27.

Billiontoone (NASDAQ:BLLN) last announced its earnings results on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.33. The firm had revenue of $108.39 million for the quarter, compared to analysts’ expectations of $95.81 million. The business’s revenue was up 83.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.39) earnings per share. Research analysts expect that Billiontoone, Inc. will post 0.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Billiontoone

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Adams Street Partners LLC purchased a new position in Billiontoone in the fourth quarter valued at $140,063,000. Baillie Gifford & Co. purchased a new stake in Billiontoone during the 4th quarter worth about $103,786,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Billiontoone during the 4th quarter worth about $39,717,000. JPMorgan Chase & Co. acquired a new position in shares of Billiontoone during the 4th quarter worth about $32,078,000. Finally, Wasatch Advisors LP purchased a new position in shares of Billiontoone in the 1st quarter valued at about $29,179,000.

Analyst Upgrades and Downgrades

BLLN has been the topic of a number of recent research reports. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. JPMorgan Chase & Co. upped their price target on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Guggenheim initiated coverage on Billiontoone in a research report on Monday, June 29th. They issued a “buy” rating and a $125.00 price target on the stock. Finally, BTIG Research lowered their price objective on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Billiontoone has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.